What is it?
5-MeO-DMT belongs to the tryptamine class and is structurally related to serotonin and melatonin.
It is often described as an "atypical psychedelic" because it acts primarily at 5-HT1A receptors,
with ~100-1000x higher affinity than 5-HT2A.
Compared with N,N-DMT, 5-MeO-DMT is far more potent, produces fewer visual effects, and is more
likely to induce deep ego dissolution and non-dual states.
Microdosing is exceptionally challenging because active doses are sub-milligram, consumer scales
cannot measure them reliably, the dose-response curve is steep, and research on microdosing is
limited.
π¨ Important Warnings
Please read all warnings carefully before use.
Combining with MAOIs is potentially fatal due to serotonin syndrome risk.
Loss of consciousness and motor control is common; aspiration risk if vomiting occurs.
Deaths have been documented in uncontrolled settings.
Avoid with psychosis, bipolar I, cardiovascular disease, epilepsy, pregnancy, or severe organ impairment.
Extreme potency and steep dose-response make microdosing unusually risky and hard to measure.
Reactivations (spontaneous re-experiencing) can occur days to months later.
β Contraindications
Conditions that make use unsafe or require strict medical oversight.
| Category | Contraindication | Risk Level |
|---|---|---|
| Psychiatric | Schizophrenia, psychotic disorders |
ABSOLUTE
|
| Psychiatric | Bipolar I disorder |
ABSOLUTE
|
| Psychiatric | Current psychosis or active suicidal ideation |
ABSOLUTE
|
| Cardiovascular | Coronary artery disease, heart failure |
ABSOLUTE
|
| Cardiovascular | Uncontrolled hypertension |
ABSOLUTE
|
| Cardiovascular | Arrhythmias, stroke history |
ABSOLUTE
|
| Neurological | Epilepsy, seizure disorders |
ABSOLUTE
|
| Other | Pregnancy/breastfeeding |
ABSOLUTE
|
| Other | Severe liver or kidney impairment |
ABSOLUTE
|
| Psychiatric | Personal/family history of psychosis |
RELATIVE
|
β οΈ Interactions & Combinations
Important information about drug interactions and combinations. Always consult a physician before combining.
MAOIs (phenelzine, tranylcypromine, Syrian rue, ayahuasca)
Serotonin syndrome, blocked metabolism
5-MeO-DMT is metabolized by MAO-A. MAOIs block metabolism and can dramatically increase exposure with potentially fatal outcomes. Documented deaths exist.
Mechanism: MAO-A inhibition prevents clearance and raises serotonin toxicity risk.
Lithium (carbonate/citrate)
Seizures, unpredictable effects
Lithium combined with psychedelics has been associated with a high seizure rate and medical complications in observational research.
SSRIs (fluoxetine, sertraline, escitalopram)
Serotonin syndrome risk
Theoretical serotonin toxicity risk; fluoxetine also inhibits CYP2D6. Washout typically 2+ weeks (5-6 weeks for fluoxetine).
SNRIs (venlafaxine, duloxetine)
Serotonin syndrome risk
Theoretical serotonin toxicity risk; effects may persist for months after discontinuation. Avoid combining.
Tricyclic antidepressants (imipramine, amitriptyline, clomipramine)
Effect intensification
May unpredictably intensify effects via postsynaptic receptor sensitization.
Antipsychotics (risperidone, olanzapine, quetiapine, haloperidol)
Effect attenuation
Most are 5-HT2A antagonists and can block effects; haloperidol may increase anxiety.
Stimulants (amphetamine, methylphenidate, cocaine, MDMA)
Cardiovascular burden
Combined cardiovascular stress may be dangerous; bupropion increases seizure risk.
π§ͺ Preparation
Preparation methods and handling tips for accurate dosing.
Because active doses are extremely small, volumetric dosing with a verified salt form is the
only reliable method for sub-milligram accuracy. Use synthetic material from trusted sources,
avoid toad-derived secretion, and label concentrations clearly.
Volumetric Dosing (Essential)
The only reliable method for sub-milligram accuracy due to extreme potency.
Steps:
- Weigh a larger amount (50-100 mg) to minimize scale error
- Choose solvent: water or propylene glycol for salts; ethanol for freebase
- Calculate concentration (e.g., 50 mg in 50 ml = 1 mg/ml)
- Mix thoroughly; warm gently if needed for full dissolution
- Measure doses with an oral syringe (0.1 ml markings)
- Use lower concentrations for sub-mg doses (e.g., 0.1 mg/ml)
Precision Weighing (Sub-Psychedelic Only)
Feasible for 6 mg+ doses with high-quality milligram scales; not for true microdoses.
Steps:
- Calibrate scale before each use with certified weights
- Use weigh paper or a weigh boat; tare before adding material
- Weigh in a draft-free environment
- Take multiple measurements and average
- Use salt forms for consistency
- Account for salt/freebase conversion when needed
π Microdosing Protocols
Recommended protocols and regimens for microdosing this substance.
Modified Fadiman Protocol for 5-MeO-DMT
Dosage:
Sub-threshold dosing (<=0.5 mg vaporized equivalent) via volumetric solution only.
Schedule:
Day 1: dose, Day 2-3: rest, repeat
Adaptation of the Fadiman protocol requiring extreme caution due to potency and variability. No validated microdosing protocol exists; this approach is anecdotal.
Detailed Schedule:
- Day 1: Sub-threshold dose (<=0.5 mg via volumetric solution)
- Day 2: Transition day - observe residual effects, journal
- Day 3: Normal day - no dose
- Day 4: Repeat cycle or extend rest if needed
- After 4-8 weeks: take a 2-4 week break
Weekly Sub-Psychedelic Protocol
Dosage:
Sublingual salt form 6-12 mg (below full psychedelic threshold).
Schedule:
Once weekly for 4 weeks
Based on the only published clinical trial (Bistue MillΓ³n et al., 2025, Neuropsychopharmacology) using weekly sublingual dosing with EEG changes. Doses may be noticeable and are not purely sub-perceptual.
Detailed Schedule:
- Week 1: Initial dose (6 mg sublingual salt form)
- Week 2: Maintain or adjust (6-9 mg)
- Week 3: Maintain or adjust (6-12 mg)
- Week 4: Final session and evaluation
- Integration period after completion
β¨ Reported Effects
Ego Dissolution
Loss of sense of self and boundaries with a feeling of unity.
Mystical Experience
About 60-75% of users report complete mystical experiences and transcendence.
Rapid Onset & Short Duration
Effects begin within seconds when vaporized and end within 15-30 minutes.
Neuroplasticity Enhancement
Single doses have been linked to 10-15% increases in dendritic spine density lasting 1+ month.
β οΈ Safety Information
Requires experienced supervision due to loss of motor control and possible unconsciousness.
Screen for cardiovascular and psychiatric risks, and complete a full medication review
(MAOIs, SSRIs/SNRIs, lithium, stimulants). Synthetic material is strongly preferred for
accurate dosing. Never use alone and keep emergency support accessible.
π¬ Scientific Research
Current research findings and clinical studies.
Phase 1 intranasal study (1-12 mg) established human pharmacokinetics with peak plasma at 8-10 minutes and half-life under 27 minutes; well tolerated.
Open-label phase 1/2 inhalation study (6-18 mg) reported 87.5% remission at day 7 with individualized dosing and no serious adverse events.
Two-photon microscopy study found a 10-15% increase in dendritic spine density lasting at least one month after a single dose.
Comprehensive review establishing 5-MeO-DMT as an atypical psychedelic with high 5-HT1A affinity and rapid antidepressant signals.
Weekly sublingual dosing (6-12 mg) produced dose-dependent EEG modulation and was well tolerated in a controlled setting.
βοΈ Legal Status
Current legal status in various jurisdictions. Always respect local laws.
| Jurisdiction | Status | Details |
|---|---|---|
|
United States (Federal)
(2011) |
Schedule I Controlled
|
Illegal to manufacture, possess, or distribute. DEA Final Rule effective January 19, 2011. Penalties can reach up to 20 years. |
| Netherlands |
Not explicitly controlled
|
Not listed on Opium Act schedules. Available at smart shops. Retreat centers operate openly. |
| Czech Republic |
Legal (not scheduled)
|
Not listed as a controlled substance under Government Regulation 463/2013. DMT is controlled, but 5-MeO-DMT is not. |
| Canada |
Not explicitly controlled
|
Not listed in CDSA schedules. Personal possession appears legal; sale is illegal under the Food and Drugs Act. |
|
United Kingdom
(2015) |
Class A, Schedule 1
|
Controlled under the Misuse of Drugs Act 1971. Possession up to 7 years; supply up to life imprisonment. |
|
Germany
(1999) |
Anlage I (Illegal)
|
Listed in BtMG Anlage I. Possession up to 5 years; large quantities up to 15 years. |
|
Portugal
(2001) |
Decriminalized (personal use)
|
Personal possession (<=10 days' use) is an administrative offense; trafficking carries 1-15 year penalties. |
| Mexico |
Legal (traditional use)
|
Not explicitly classified. Traditional/spiritual use is protected; Bufo retreats operate legally. |
π€ Key Figures
Notable figures associated with the research and history of this substance.
Alexander Shulgin
Research chemist, psychopharmacologist
First reported 5-MeO-DMT's hallucinogenic effects in humans (1970) and published the TiHKAL entry with synthesis and dosing details.
Ken Nelson (Albert Most)
Artist, researcher
First modern person to smoke Bufo alvarius venom (1983) and author of the influential 1984 pamphlet that sparked wider interest.
Stanislav Grof
Psychiatrist, psychedelic therapy pioneer
Developed frameworks for ego dissolution and transpersonal experiences relevant to 5-MeO-DMT phenomenology.
Martin W. Ball
Entheogenic researcher, author
Coined the term "The God Molecule" for 5-MeO-DMT and authored multiple books on its use and integration.
Alan K. Davis
Psychedelic researcher (Johns Hopkins)
Published key epidemiological studies on 5-MeO-DMT outcomes in naturalistic settings.
π Scientific Research
PubMed: 5-MeO-DMT Clinical Pharmacology Review (2022)
Comprehensive review of pharmacology, mechanisms, and therapeutic potential.
https://pubmed.ncbi.nlm.nih.gov/35285521/ClinicalTrials.gov: 5-MeO-DMT Trials
Registry of ongoing clinical trials in depression and other conditions.
https://clinicaltrials.gov/search?cond=5-MeO-DMTErowid 5-MeO-DMT Vault
Harm reduction summaries and experience reports.
https://erowid.org/chemicals/5meo_dmt/MAPS Psychedelic Bibliography
Research database covering 5-MeO-DMT and related compounds.
https://maps.org/resources/psychedelic-bibliographyF.I.V.E. (5-MeO-DMT Information & Vital Education)
Harm reduction organization focused on safety and contraindications.
https://www.integratedexchange.org/β FAQ
How long does onset take?
When vaporized, effects begin within 5-30 seconds, peak in 1-5 minutes, and total duration is
usually 15-30 minutes.
How should it be stored?
Store in amber glass vials, airtight with desiccant, at 4Β°C to -20Β°C. Salt forms are more
stable than freebase. Shelf life is typically 1-3 years when stored properly.
Synthetic vs. natural: what is safer?
Synthetic 5-MeO-DMT is preferred for consistent purity, accurate dosing, and conservation.
Toad secretion varies widely in content and may include cardiotoxic bufagins.
Can it be combined with supplements?
Avoid 5-HTP, St. John's Wort, and stimulant supplements. Discontinue supplements 1-2 weeks
before use.
How can quality be assessed?
Use reagent testing kits (Marquis, Mecke, Ehrlich). Ehrlich should turn purple. High-purity
synthetic material is usually white to off-white crystalline powder.
What safety considerations are specific to 5-MeO-DMT?
Complete loss of motor control, potential unconsciousness with vomiting risk, reactivations,
extreme potency, and potentially fatal MAOI interactions.
Important Legal Notice
β οΈ Personal Responsibility
You use this application entirely at your own risk and responsibility. MicrodosingDiary is only a tool for recording personal experiences.
π« Not a Medical Service
This application IS NOT a medical tool, does not provide medical advice, does not diagnose or treat any conditions. Always consult a qualified physician.
βοΈ Legislation and Laws
Many substances used for microdosing are illegal in many countries. Users are fully responsible for complying with local laws. The application does not support or promote illegal activity.
β No Guarantees
We provide no guarantees regarding results, safety or efficacy of microdosing. All information is for informational purposes only.
π Age Restriction
Application is intended only for persons over 18 years of age. By using the application you confirm that you are an adult.
π Data Privacy
Your data is private and encrypted. We never share it with third parties without your consent. Application is for personal use only.
By using this application you accept all the above risks and waive any claims against the application operator.